NeuroSense Therapeutics (NRSN) to Release Quarterly Earnings on Wednesday

NeuroSense Therapeutics (NASDAQ:NRSN) will likely be releasing its Q4 2025 results before the market opens on Wednesday, March 25th. Analysts expect NeuroSense Therapeutics to post earnings of ($0.1050) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, April 6, 2026 at 4:00 PM ET.

NeuroSense Therapeutics Trading Up 0.9%

Shares of NASDAQ:NRSN opened at $0.82 on Wednesday. The company has a 50-day moving average price of $0.93 and a two-hundred day moving average price of $1.02. NeuroSense Therapeutics has a twelve month low of $0.68 and a twelve month high of $2.60.

Institutional Trading of NeuroSense Therapeutics

A number of hedge funds have recently made changes to their positions in NRSN. Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics in the 2nd quarter worth approximately $54,000. Squarepoint Ops LLC increased its position in NeuroSense Therapeutics by 91.0% during the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after buying an additional 45,450 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in NeuroSense Therapeutics during the third quarter valued at $26,000. 1.04% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on NRSN. D. Boral Capital restated a “buy” rating and set a $14.00 price target on shares of NeuroSense Therapeutics in a research note on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Monday, December 29th. Roth Mkm assumed coverage on shares of NeuroSense Therapeutics in a report on Tuesday, March 10th. They set a “buy” rating and a $3.00 target price on the stock. Finally, Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.50.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.